BACKGROUND Tumor lysis syndrome is a rare and potentially fatal complication of oncologic treatments, especially in solid tumors. To the best of our knowledge, tumor lysis syndrome has never been reported after trastuzumab and pertuzumab combination therapy. Knowledge of risk factors and active prevention proceedings is of utmost importance to avoid fatal outcomes. CASE PRESENTATION We presen...

Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not been associated with a case of tumor lysis syndrome. We present the case of a patient who develop...

The tumor lysis syndrome (TLS), characterized by hyperkalemia, hyperuricemia, hyperphosphatemia and secondary hypocalcemia, is a consequence of treatmentinduced or spontaneous tumor cell death. It usually occurs a few hours to a few days after commencing cytotoxic chemotherapy for tumors with a high percentage of proliferating and drug-sensitive cells. Cell death leads to the release of potassi...

Tumor lysis syndrome (TLS) describes the clinical and laboratory sequelae that result from the rapid release of intracellular contents of dying cancer cells. It is characterized by the release of potassium, phosphorous, and nucleic acids from cancer cells into the blood stream, with the potential to cause hyperkalemia; hyperphosphatemia and secondary hypocalcemia; hyperuricemia; AKI; and, shoul...

Tumor lysis syndrome is an oncologic emergency that usually occurs after chemotherapy in patients with hematologic malignancies. Tumor lysis syndrome is rare in cases of solid tumors, especially when it occurs spontaneously. Herein, we present a case of spontaneous tumor lysis syndrome in a 55-year-old woman who presented with dyspnea and was found to have extensive metastatic small cell lung c...

Tumor lysis syndrome is characterized by a group of metabolic derangements caused by the massive and abrupt release of cellular components into the blood following the rapid lysis of malignant cells. It is observed most frequently in patients with hematologic malignancies such as acute lymphoblastic leukemia (ALL) and Burkitt’s lymphoma after the initiation of chemotherapy, although it may also...

Tumor lysis syndrome (TLS) is a constellation of metabolic abnormalities resulting from either spontaneous or chemotherapy-induced tumor cell death. Tumor cytotoxicity releases intracellular contents, including nucleic acids, proteins, and electrolytes into the systemic circulation and may lead to development of hyperuricemia, hyperphosphatemia, hypocalcemia, andhyperkalemia.Clinically, this re...

Definition: Tumor lysis syndrome (TLS) is characterized by a group of metabolic derangements including hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and uremia.caused by the massive and abrupt release of cellular components into the blood after the rapid lysis of malignant cells. It is observed most frequently in patients with malignancies with high proliferative rate, large tum...

Tumor lysis syndrome (TLS) is a life-threatening condition due to malignant tumor cell resulting in severe metabolic derangements that require prompt recognition and management prevent progression end-organ damage death. This case describes patient presenting with clinical laboratory abnormalities complicated by multi-organ dysfunction concerning spontaneous TLS from suspected undiagnosed malig...